Eli Lilly & Co.’s pharmaceutical rebates and discounts to US payers in the commercial and government-sponsored insurance markets rose by nearly 30% in 2016 as the company fought to gain favorable access for its diabetes drugs and other products.
Rebate and discount payments totaled $7.69bn in 2016, compared with $5.93bn the year before, the company disclosed in its recently-released...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?